BofA analyst Alec Stranahan lowered the firm’s price target on Novavax (NVAX) to $9 from $10 and keeps a Neutral rating on the shares. The firm expects the predominate focus for the Q2 report and call will be on management guidance around the upcoming vaccine season, the analyst tells investors in an earnings preview for its small-to-mid cap biotech coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Novavax’s Promising Vaccine Study: A Potential Game-Changer for COVID-19 and Flu
- Novavax’s Latest Vaccine Study: Key Insights for Investors
- Novavax Completes Phase 3 Booster Vaccine Study: Key Insights for Investors
- Novavax Shareholders Approve Key Proposals at Annual Meeting
- Novavax Faces Challenges Amid Stock Decline